확장기 소세포폐암에서 1차 치료로서 Irinotecan + Cisplatin 복합요법의 임상적 결과
Phase Ⅱ Study of Irinotecan Plus Cisplatin as First Line therapy in Extensive Small-Cell Lung Cancer
박성훈 (원광대학교)
박정현 (원광대학교)
김휘정 (원광대학교)
김학렬 (원광대학교)
양세훈 (원광대학교)
정은택 (원광대학교)
김소영 (원광의대)
정종훈 (원광의대)
- 다운로드 수
- 조회수
초록
연구배경: Toptisomerase I 억제제인 irinotecan 과 소세포폐암 치료의 근간인 cisplatin의 복합화학용법을 확장기 소세포폐암 환자에게 1차 치료법으로 실시하여 반응률, 생존율 및 부작용을 확인하였다.방 법: 2002년 6월부터 2005년 2월까지 확진된 확장기 소세포폐암 환자 39명에게 irinotecan 60mg/㎡, 제 1, 8, 15일째 cisplatin 60mg/㎡ 제1일째에 28일 간격으로 4회 투여하였다.결 과: 반응률은 77%(완전반응 8%), 중앙생존기간은 14.8개월, 1-및 2-년 생존율은 60.9%, 27.6%였으며, 중앙 무진행생존기간은 8.4개월, 6-및 12-개월 무진행생존율은 75.0%, 18.8%였다. WHO grade 3 이상의 부작용은 백혈구 감소증 23%, 설사 26%였으나, 심한 설사때문에 2명은 치료방법을 바꾸었고, 1명은 사망하였다.
- keywords
- Small-cell lung cancer, Irinotecan, Cisplatin., Small-cell lung cancer, Irinotecan, Cisplatin.
Abstract
Background: Irinotecan (topoisomerase I inhibitor) is effective as a monotherapy against small-cell lung cancer(SCLC). Cisplatin is also an important drug against SCLC. A phase II study of irinotecan combined with cisplatin was carried out to evaluate the efficacy and toxicity of this combined regimen as a first line treatment in patients with extensive SCLC. Methods: Thirty-nine patients with previously untreated extensive SCLC were enrolled in this study. Irinotecan 60mg/㎡ was administered intravenously on days 1, 8 and 15, and in combination with cisplatin 60mg/㎡ on day 1 and every 28 days thereafter. Four cycles of chemotherapy were given to the patients. Results: The overall response rate was 77% with a complete response (CR) rate of 8%. The median survival time, 1- and 2-year survival rate were 14.8 months, 60.9% and 27.6%, respectively. The median progression free survival time, 6-and 12-month progression free survival rate were 8.4 months, 75% and 18.8%, respectively. The WHO grade 3 or more toxicity encountered were leukopenia (23%), diarrhea (26%). Two patients changed their chemotherapeutic regimen and one patient died from severe diarrhea. Conclusion: The combination of irinotecan and cisplatin is effective as a first line therapy in extensive SCLC is effective , but has severe or fatal diarrhea as toxicity. (Tuberc Respir Dis 2006; 61: 143-149)
- keywords
- Small-cell lung cancer, Irinotecan, Cisplatin., Small-cell lung cancer, Irinotecan, Cisplatin.
참고문헌
Jeong ET, (2000) Clinical survey of lung cancer in Korea,
Witta SE, (2005) chemotherapy for small cell lung cancer, Lippincott Williams and Wilkins
Nitta K, Antitumor activity of 7-ethyl- 10-[4- a novel water-soluble derivative of camptothecin against murine tumors,
Masuda N, (1992) CPT-11:A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer,
Fujiwara Y, (1998) Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer,
Noda K, (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer,
No, (1979) WHO handbook for reporting the results of cancer treatment,
Roth BJ, (jclinoncol1992) Randomized study of cyclophosphamide and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer a phase III trial of the Southeastern Cancer Study Group,
Chute JP, (1999) Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer:perceptible progress,
Hsiang YH, (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I,
Masuda N, Phase I study of weekly intravenous infusions of CPT-11 a new derivative of camptothecin in the treatment of advanced non-small -cell lung cancer,
Hanna N, (2006) Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer,
Ihde DC, (1994) Prospective randomized comparison of high dose and standard dose etoposide and cisplatin chemotherapy on patients with extensive stage small cell lung cancer,
Beutler E, (1998) Racial variability in the UDP-glucuronosyltransferase 1 a balanced polymorphism for regulation of bilirubin metabolism,
Font A, (2001) UGT1A1 genotyping correlates with toxicity and survival in non-small cell lung cancer(NSCLC)patients treated with second- line CPT-11/docetaxel,
Han JY, (2006) Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients With non-small-cell lung cancer treated with irinotecan and cisplatin,
Jeong HL, (2005) Phase II trial of irinotecan plus cisplatin combinations on first line therapy for patients with small cell lung cancer,
- 다운로드 수
- 조회수
- 0KCI 피인용수
- 0WOS 피인용수